Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial by Verma, S. et al.
Key Words: diabetes mellitus  
◼ liraglutide
The causal relationship between low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular events has been well established.1 In peo-ple with type 2 diabetes mellitus, LDL-C lowering with statins is strongly en-
dorsed by clinical practice guidelines, with suggested LDL-C target levels including 
<100 mg/dL for high-risk patients, <70 mg/dL for very high-risk patients,2–4 and 
≤55 mg/dL in patients with cardiovascular disease at extreme risk.2 Because LDL-C 
is a dominant pathophysiological mechanism of atherogenesis, questions pertain 
to whether newer antiatherosclerotic and cardiovascular protective therapies ex-
hibit efficacy, even in the setting of low LDL-C. In this post hoc analysis of the 
LEADER trial, we evaluated the efficacy of liraglutide on cardiovascular outcomes 
and mortality across the spectrum of baseline LDL-C and statin use.5
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results; https://www.clinicaltrials.gov; unique identifier: NCT01179048) 
was a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus 
placebo in 9340 patients with type 2 diabetes mellitus and high cardiovascular risk 
(median follow-up, 3.8 years).5 The primary outcome was a composite of cardio-
vascular death, nonfatal myocardial infarction, or nonfatal stroke (major adverse 
cardiovascular events [MACEs]). The key secondary outcome (expanded MACEs) 
also included coronary revascularization, hospitalization for unstable angina, and 
hospitalization for heart failure. The ethics committee or institutional review board 
at each center approved the trial protocol. Patients provided informed consent. Car-
diovascular outcomes were prospectively adjudicated by an independent, blinded 
event adjudication committee. Tests for trends in risk of first MACE and cardiovas-
cular death across the 3 baseline LDL-C groups were performed with the Cochran-
Armitage test for trend applied in a logistic regression adjusted for prior cardiovas-
cular disease. The treatment effect of liraglutide versus placebo on cardiovascular 
outcomes by LDL-C level <50, 50 to 70, and >70 mg/dL and statin use at baseline 
was estimated with Cox regression with treatment, groups by LDL-C level, and 
the interactions of both as factors and further adjusted for baseline cardiovascular 
risk factors (sex, region, smoking history, prior cardiovascular disease, antidiabetes 
medications, age, diabetes duration, and estimated glomerular filtration rate).5
In LEADER, 9187 patients had baseline LDL-C measured: 926 (10.1%), 2021 
(22.0%), and 6240 (67.9%) had LDL-C <50, 50 to 70, or >70 mg/dL, respec-
tively. Baseline demographics and risk factors were well balanced across LDL-C 
levels, except that the highest LDL-C group had a higher proportion of women, a 
lower incidence of prior myocardial infarction or stroke, and a lower rate of statin 
use compared with the other 2 groups. Mean LDL-C in the 3 groups was 38.7 
(SD, 7.7), 61.9 (SD, 3.9), and 108.3 (SD, 30.9) mg/dL, respectively. At baseline, 
72% were on a statin, with an additional 10% having statin added during the 
course of the study (9% in the liraglutide and 11% in the placebo group).5
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Higher baseline LDL-C was associated with greater 
risk of MACEs. The crude proportion of patients expe-
riencing MACEs was 11.7% in the LDL-C <50 mg/dL 
group, 13.9% in the LDL-C 50 to 70 mg/dL group, and 
14.2% in the LDL-C >70 mg/dL group (adjusted trend 
test, P=0.01). Likewise, a higher crude proportion of 
cardiovascular death was observed across increasing 
LDL-C (4.3%, 4.6%, and 5.6% for the LDL-C groups, 
respectively; adjusted trend test, P=0.03).
Liraglutide consistently reduced MACEs across 
the 3 LDL-C groups. Baseline adjusted hazard ra-
tios were 0.72 (95% CI, 0.49–1.06), 0.82 (95% CI, 
0.65–1.04), and 0.90 (95% CI, 0.79–1.03), respec-
tively (pinteraction=0.51). Results were similar for expanded 
MACEs and individual MACE components, including 
cardiovascular mortality (Figure). With further stratifica-
tion by atherosclerotic cardiovascular disease at base-
line (yes/no), homogeneity for treatment differences 
across the 3 LDL-C groups was preserved for MACEs 
(pinteraction=0.71 and 0.69, respectively). In a sensitivity 
analysis, with patients with LDL-C divided at baseline 
above and below the median (84.2 mg/dL), liraglutide 
reduced MACEs in both groups (hazard ratio, 0.88 
[95% CI, 0.76–1.03] and 0.86 [95% CI, 0.73–1.01], 
respectively [pinteraction=0.85]). The cardiovascular effect 
of liraglutide was also evaluated across alternative lipid 
parameters with similar results. The hazard ratios for 
liraglutide versus placebo for MACEs in those above 
and below median high-density lipoprotein cholesterol 
(44 mg/dL) were 0.87 (95% CI, 0.74–1.04) and 0.86 
(95% CI, 0.74–0.99), respectively (pinteraction=0.89), and 
for the median non–high-density lipoprotein cholesterol 
(118 mg/dL) were 0.85 (95% CI, 0.73–0.99) and 0.88 
(956% CI, 0.75–1.04), respectively (pinteraction=0.77).
The hazard ratio for liraglutide versus placebo for 
MACEs was 0.83 (95% CI, 0.73–0.95) in statin users and 
0.97 (95% CI, 0.79–1.20) in nonusers (pinteraction=0.20).
Taken together, the results of this post hoc analy-
sis from the LEADER trial suggest that the benefits of 
liraglutide on cardiovascular outcomes and mortal-
ity appear consistent in patients with type 2 diabetes 
mellitus at high cardiovascular risk, independently of 
LDL-C level, and persist even in the setting of very low 
baseline LDL-C and concomitant statin use. These data 
suggest that the potential antiatherosclerotic effects of 
glucagon-like peptide-1 receptor agonists are comple-
mentary to lipid lowering and that there is an additional 
risk reduction to be achieved on top of optimal cardio-
vascular care.
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